Page 8 of 39 · 913 questions tagged clinical-trials.
The case in front of me: hair thinning · tirzepatide · SURMOUNT-3. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
I am trying to understand the logic of putting glucagon receptor agonism into a weight-loss molecule, because on the face of it it sounds like a mistake. Glucagon…
What I have: FLOW · headache · 15 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Concretely: SURMOUNT-1 · vomiting. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…
Stated plainly: STEP 1 · dizziness · 40 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline.…
The case in front of me: STEP 2 · injection-site erythema · 60 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
For reference: PIONEER-4 · survodutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…
Stated plainly: SURMOUNT-1 · reflux · 2.5 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
For reference: tirzepatide · SURMOUNT-4. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to…
The particulars: oral semaglutide · minus 80 °C. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I…
The clinician who ordered the panel was not concerned; I would still like to understand it. The units are where I keep going wrong, so please be explicit about them.…
Conditions: SURMOUNT-5 · dizziness. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
Setup, so nobody has to ask: SURMOUNT-1 · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I am working with: ESSENCE · cagrilintide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have…
The specifics, since they change the answer: SELECT · 60 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My…
Numbers first: dizziness · dulaglutide · SELECT. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…
The particulars: liraglutide · cagrilintide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and…
Concretely: survodutide · 2–8 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Has anyone…
Details up front: SURMOUNT-4 · orforglipron. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…
Stated plainly: SURMOUNT-OSA · 15 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I am trying to build something sustainable rather than something…
The case in front of me: REDEFINE-1 · dizziness · 20 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers…
The clinician who ordered the panel was not concerned; I would still like to understand it. This is one of those things that everyone repeats and nobody derives. This…
Concretely: ecnoglutide · mazdutide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it works; the question…